<DOC>
	<DOCNO>NCT00176254</DOCNO>
	<brief_summary>This study utilize two cycle Paclitaxel Carboplatin chemotherapy follow four small dos radiation , prior treatment ( surgery radiation ) . This study evaluate radiation chemoenhancer increase response rate initial therapy .</brief_summary>
	<brief_title>Paclitaxel , Carboplatin Radiotherapy Induction Therapy Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>Cancers head neck ( H &amp; N ) comprise 5 % cancer , 40,000 new case diagnose annually . Surgery follow irradiation irradiation alone standard care locally advanced Stage III IV patient . With approach , few 30 % patient achieve long-term remission , recur locoregionally . Neoadjuvant chemotherapy administer prior definitive therapy response rate range 60-90 % ; pathologic complete response ( CR ) rate document 30-70 % clinical responder . However , large randomize trial show improvement overall survival . Because induction chemotherapy alone appear improve long-term disease free survival advance head neck cancer , concomitant chemotherapy radiation pursue patient locally advanced head neck cancer . Improved disease-free survival demonstrate variety agent . The concept synergy radiation chemotherapy well establish vitro . Various schedule radiation chemotherapy utilized include weekly chemotherapy radiation , chemotherapy give every three week hyperfractionated radiation alternate chemotherapy radiation . One excite new chemotherapeutic agent , Paclitaxel show radiosensitize cancer cell line vitro . Recent study add Carboplatin Paclitaxel tandem concurrently radiation hope improve response rate . From in-vitro data , appear optimum schedule combination Paclitaxel radiation first induce G2/M arrest Paclitaxel follow radiation therapy . In recent study Chendil , et al , novel radiation scheme appear enhance response p53 wild type p53 mutant cancer cell line chemotherapy . In vitro data Carboplatin also indicate additive effect give prior irradiation use various cell line . What evaluate , whether neoadjuvant regimen Paclitaxel Carboplatin follow 4 small fraction radiation give safely effect improve response rate patient bulky T2 , Stage III IV H &amp; N cancer . We propose use two cycle Paclitaxel Carboplatin follow four small fraction radiation , prior definitive treatment ( surgery radiation ) . It hop use radiation chemoenhancer increase response rate induction therapy population patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Adult patient great 18 year age . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . 3 . Patients pathologically document bulky T2 , III IV squamous cell cancer head neck ( exclude M1 disease ) , within 2 month diagnosis . Bulky T2 tumor define volume disease great 35 cm3 measure CT MRI scan ( 26 ) . 4 . Patients medically fit undergoing chemotherapy . Specifically : 1. evidence active angina pectoris ventricular arrhythmia ; myocardial infarction within last six month . ( Patients medically control hypertension congestive heart failure eligible . ) 2. absolute neutrophil count &gt; 1000/uL platelet count &gt; 100,000/microliter ( uL ) 3. serum total bilirubin &lt; 1.5 mg/dL 4 . Creatinine Clearance great 50 ml/min Using actual calculate creatinine clearance use formula : ( 140 age ) x ( wgt kg ) */ ( serum creatinine ) x ( 72 ) *= multiply 0.85 female 5. preexist grade I neuropathy exists , patient must willing risk worsen neuropathy secondary Paclitaxel . Patients grade II great neuropathy exclude study . 6. ability give write , inform consent participate trial . 5 . Patients measurable disease determine MRI CT scan evaluable disease determine panendoscopy eligible enrollment study . 1 . Pregnant female . Males woman childbearing potential must use effective contraception order prevent pregnancy therapy . 2 . Patients history previous current malignancy site diagnose within last 5 year , exception adequately treat carcinoma insitu cervix basal squamous cell carcinoma skin . Patients history malignancy , remain free recurrence metastasis great five year eligible . 3 . Patients active infection eligible protocol infection treat symptom clinically resolve . 4 . Patients history allergy drug utilize Cremophor formulation . 5 . Prior induction chemotherapy , prior irradiation surgery allow . 6 . Patients metastatic disease eligible study . 7 . Patients grade II great peripheral neuropathy exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>head neck</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>squamous cell</keyword>
	<keyword>carcinoma</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>induction therapy</keyword>
</DOC>